The authors report seven-year outcomes of the PARTNER 3 trial comparing transfemoral transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) in 1,000 low-risk patients with severe, symptomatic aortic stenosis. At seven years, there were no significant differences between groups in the primary composite endpoints of death, stroke, or rehospitalization (34.6 percent for TAVR vs 37.2 percent for SAVR; HR 0.87, 95 percent CI 0.70–1.08). Mortality was similar (19.5 percent vs 16.8 percent), as were stroke (8.5 percent vs 8.1 percent), and valve failure (6.9 percent vs 7.3 percent). Valve hemodynamics and patient-reported outcomes remained stable. TAVR resulted in less atrial fibrillation but had higher rates of pacemaker implantation and paravalvular regurgitation.